KYMR•benzinga•
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $52
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga